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Abstract
The 148 Isoleucine to Methionine protein variant 
(I148M) of patatin-like phospholipase domain-con-
taining 3 (PNPLA3), a protein is expressed in the liver 
and is involved in lipid metabolism, has recently been 
identified as a major determinant of liver fat content. 
Several studies confirmed that the I148M variant pre-
disposes towards the full spectrum of liver damage 
associated with fatty liver: from simple steatosis to 
steatohepatitis and progressive fibrosis. Furthermore, 
the I148M variant represents a major determinant of 
progression of alcohol related steatohepatitis to cir-
rhosis, and to influence fibrogenesis and related clini-
cal outcomes in chronic hepatitis C virus hepatitis, and 
possibly chronic hepatitis B virus hepatitis, hereditary 
hemochromatosis and primary sclerosing cholangitis. 
All in all, studies suggest that the I148M polymorphism 
may represent a general modifier of fibrogenesis in liver 
diseases. Remarkably, the effect of the I148M variant 
on fibrosis was independent of that on hepatic steatosis 
and inflammation, suggesting that it may affect both 
the quantity and quality of hepatic lipids and the biol-
ogy of non-parenchymal liver cells besides hepatocytes, 
directly promoting fibrogenesis. Therefore, PNPLA3 is 
a key player in liver disease progression. Assessment 
of the I148M polymorphism will possibly inform clini-
cal practice in the future, whereas the determination of 
the effect of the 148M variant will reveal mechanisms 
involved in hepatic fibrogenesis.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: The 148 Isoleucine to Methionine protein 
variant (I148M) of patatin-like phospholipase domain-
containing 3 (PNPLA3) has recently been identified as a 
major determinant of liver fat content. Several studies 
conducted in different ethnicities confirmed that I148M 
influences the full spectrum of liver damage: from simple 
steatosis to nonalcoholic steatohepatitis and progres-
sive fibrosis to hepatocellular carcinoma. Furthermore, 
I148M turned out to represent a major determinant of 
progression of alcohol related steatohepatitis, and to 
influence fibrosis progression and related clinical out-
comes in chronic hepatitis C virus hepatitis, as well as 
other in liver diseases. All in all, studies suggest that the 
PNPLA3 I148M polymorphism may represent a general 
modifier of fibrogenesis in liver diseases.
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INTRODUCTION
The clinical evolution of  chronic liver diseases is highly 
variable, and genetic factors plays a key role in determin-
ing the inter-individual susceptibility towards end-stage 
liver disease and hepatocellular carcinoma. It is now 
established that all common diseases, including type 2 
diabetes, atherosclerosis, and nonalcoholic fatty liver dis-
ease (NAFLD) among liver diseases[1], exhibit a heritable 
component of  susceptibility accounting for 30%-50% of  
risk. Indeed, also liver diseases can be considered com-
plex traits that result from environmental exposures, e.g., 
diet and physical inactivity for NAFLD, excessive alcohol 
intake for alcoholic liver disease (ALD), or infection for 
chronic viral hepatitis, acting on a susceptible polygenic 
background comprising multiple independent modifi-
ers[2]. These are generally represented by common genetic 
variants with a mild effect or rare variants associated with 
a more marked phenotype[3].
Despite initial hypothesis-driven, case-control stud-
ies identified some genetic loci associated with the pro-
gression of  liver damage, the genetic determinants of  
NAFLD remained obscure until recently[1]. By 2008, 
the first genomewide association studies in the field of  
hepatic steatosis allowed to identify the rs738409 vari-
ant, by an hypothesis free drive approach, as the single 
major genetic determinant of  hepatic fat content[4,5]. This 
sequence variation is a C > G single nucleotide change, 
encoding for the 148 Isoleucine to Methionine protein 
variant (I148M) of  Patatin-like phospholipase domain-
containing 3 (PNPLA3). The main purpose of  this re-
view is to provide an overview of  the current knowledge 
of  the PNPLA3 I148M polymorphism role in the pro-
gression of  liver disease.
NONALCOHOLIC FATTY LIVER
Ectopic fat accumulation in the liver related to systemic 
insulin resistance represents the prototypical manifesta-
tion of  NAFLD[6]. With a prevalence of  20%-34% and 
rising, NAFLD is now the most frequent liver disease in 
industrialized countries[7,8]. In a minority of  susceptible 
individuals, steatosis, that is excessive fat accumulation in 
the liver (> 5%), is associated with oxidative hepatocellu-
lar damage, inflammation and activation of  fibrogenesis, 
i.e. nonalcoholic steatohepatitis (NASH)[9,10], which can 
progress to cirrhosis and hepatocellular carcinoma[11,12]. 
NAFLD is epidemiologically associated with obesity 
and metabolic syndrome. The pathogenesis is related to 
adipose tissue insulin resistance[13], leading to an increased 
flux of  free fatty acids to the liver[14], increased lipogen-
esis induced by hyperinsulinemia, abnormal intra-hepatic 
lipid metabolism and dietary factors. Hepatic fat accumu-
lation, in turn, worsens insulin resistance and liver dam-
age, determining an increased risk of  both cardiovascular 
and liver related mortality[15-17]. 
Besides hepatocytes, two cell types play a key role in 
the pathogenesis of  NASH. Kupffer cells are the hepatic 
macrophages that under basal conditions are involved 
in the maintenance of  immune homeostasis, but during 
NASH become activated by intestinal bacterial products 
and oxidized lipids via Toll-like receptor-4 and secrete re-
active oxygen species, chemokines and several cytokines, 
thereby orchestrating inflammation[18]. Hepatic stellate 
cells are hepatic pericytes localized between sinusoidal 
endothelial cells and the hepatocytes, which in quiescent 
conditions store lipids and retinoids, secrete extracel-
lular matrix, and regulate blood flow. Upon activation 
in NASH, stellate cells release retinoids, undergo myofi-
broblast transition, secrete type 1 collagen and a variety 
of  fibrogenic mediators thereby initiating the process of  
fibrogenesis[19,20].
GENETIC PREDISPOSITION TO FATTY 
LIVER
The risk of  NAFLD is highly variable even in individuals 
with obesity and type 2 diabetes. Furthermore, even if  
the majority of  obese subjects with metabolic syndrome 
develop simple steatosis, only about one third has NASH, 
and a minority progresses to more severe forms of  the 
disease. 
Epidemiological, familial and twin studies provide evi-
dence for a component of  hereditability of  liver fat con-
tent and NAFLD[21,22]. Indeed, NAFLD is more prevalent 
in Hispanics compared to Europeans, and less common 
in African-Americans, and this difference is not explained 
by diabetes and obesity[22,23]. Family studies demonstrated 
a strong heritability of  NASH[21,24,25]. Accordingly, twin 
studies shown that, in subjects without viral hepatitis and 
alcohol abuse, alanine aminotransferases (ALT) levels and 
liver fat content are strongly heritable traits, with genetic 
factors explaining up to 60% of  variability[26,27]. Overall, 
evidences indicate that about half  of  steatosis variability, 
determined by biochemical indices or noninvasive as-
sessment of  liver fat, is inherited[1]. Therefore, several 
hypothesis-driven studies tried to evaluate the role of  
candidate genetic variants in the susceptibility to NAFLD 
and progressive NASH, with the goal of  identifying dis-
ease markers or potential drug targets, but with inconsis-
tent results[1].
PNPLA3 I148M IS A MAJOR 
DETERMIMANT OF FATTY LIVER
In 2008, two independent genome-wide association 
studies linked the common rs738409 polymorphism of  
PNPLA3 (I148M) with hepatic fat content and ALT 
levels[4,5]. In particular, a genomewide scan of  the associa-
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Figure 1  Hypothetical mechanism of hepatic fat accumulation associated with the 148 Isoleucine to Methionine protein variant patatin-like phospholi-
pase domain-containing 3 polymorphism. ER: Endoplasmic reticulum; LPA: Lyso-phosphatidic acid; PA: Phosphatidic acid; Tg: Triglycerides; ?: To be confirmed; 
PNPLA3: Patatin-like phospholipase domain-containing 3.
tion of  non-synonymous sequence variations in the Dal-
las Heart Study revealed a very strong association of  in-
creased fat content with a single missense variant, I148M, 
in PNPLA3[4].
Remarkably, the association between PNPLA3 I148M 
and liver fat was independent of  major differences in 
body composition, diabetes and serum lipoprotein levels. 
Furthermore, the 148M at risk allele was more prevalent 
in Hispanics [minor allele frequency (MAF): 0.49] than in 
Europeans (MAF: 0.23), and less common in Afro-Amer-
icans (MAF: 0.17) explaining a consistent fraction of  the 
inter-ethnic variability in NAFLD susceptibility[4,28]. 
Since then, several studies and a recent meta-analysis 
have replicated the association between the I148M poly-
morphism and NAFLD in all ethnic groups, both in 
adults and in the developmental age[28-41]. The associa-
tion of  the I148M variant with hepatic lipid content is 
exposed in the presence of  other risk factors, such as 
severe obesity[32], visceral adiposity[42], increased intake of  
sugars[43] or omega-6 poly-unsaturated fatty acids[44], and 
other genetic factors[45,46]. Vice versa, weight loss results 
in a rapid decrease of  intra-hepatic fat and of  indices of  
liver damage in subjects homozygous for the 148M vari-
ant[47]. All in all, these data suggest that the 148M variant 
becomes a critical factor determining hepatocellular fat 
accumulation when stressing factors such as increased 
flux of  free fatty acids related to adipose tissue insulin 
resistance in visceral obesity, increased lipogenesis stimu-
lated by hyperinsulinemia and carbohydrates, or altered 
lipid metabolism intervene.
FUNCTION OF wILD-TYPE AND MUTANT 
PNPLA3
PNPLA3, also called adiponutrin, encodes a 481 amino 
acid protein with a molecular mass of  approximately 53 
kDa that in humans is mainly expressed in intracellular 
membrane fractions in hepatocytes[48], and is induced in 
the liver after feeding and during insulin resistance by the 
master regulator of  lipogenesis Steroid Regulatory Ele-
ment Binding Protein-1c[49].
Wild-type (148I) PNPLA3 has lipolytic activity to-
wards triglycerides[48,50]. The 148M mutation determines a 
critical aminoacidic substitution next to the catalytic do-
main, likely reducing the access of  substrates and reduc-
ing the PNPLA3 enzymatic activity towards glycerolipids, 
thereby leading to the development of  macrovescicular 
steatosis[48,50]. However, other reported a gain of  lipo-
genic function associated with the 148M variant, which 
would acquire the ability to synthesize phosphatidic acid 
from lysophosphatidic acid[51]. In addition, results deriv-
ing from murine models gave contradictory results[52-55]. 
The issue of  the functional consequences of  the I148M 
polymorphism is therefore still intensively debated, and it 
may be hypothesized that PNPLA3 has additional physi-
ological substrates. Human studies have also suggested a 
possible direct or indirect influence of  PNPLA3 geno-
type on adipose tissue biology[56,57], which however awaits 
replication.
A model depicting hypothetical mechanisms of  
hepatic fat accumulation associated with the I148M 
PNPLA3 polymorphism is shown in Figure 1.
ASSOCIATION OF PNPLA3 I148M 
wITH PROGRESSIVE FIBROSIS IN 
STEATOHEPATITIS
Even if  steatosis severity is a risk factor for NASH and 
progressive disease in NAFLD[58], the association is not 
invariable, and hepatocellular fat is believed to represent 
Dongiovanni et al . PNPLA3 and liver disease
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patients. The presence of  steatosis has been associated 
with more aggressive histological features, faster progres-
sion of  fibrosis, and poorer response to therapy[65-68]. 
Hepatic steatosis favors hepatitis C virus (HCV) life-
cycle[69], and both viral and host factors are believed to 
contribute to its pathogenesis[67,70-73]. It became soon clear 
that the I148M polymorphism is a major determinant of  
the susceptibility to steatosis in also CHC, in particular 
in patients not infected by genotype 3 strains that per se 
strongly induces steatosis by altering very low density 
lipoproteins export[74-77]. This model is also consistent 
with the recent finding of  a nonsense mutation of  APOB 
in humans causing hypo-beta-alipoproteinemia and a 
massive history of  severe steatosis associated with devel-
opment of  hepatocellular carcinoma in carriers of  this 
mutation[78].
Studies that specifically evaluated the association 
between the I148M PNPLA3 variant and fibrosis pro-
gression in CHC are reported in Table 1. As in NAFLD 
and ALD, the effect of  the 148M mutation was not lim-
ited to predisposition to steatosis, but extended towards 
progressive fibrosis and cirrhosis development[75-77,79]. 
Interestingly, the size effect of  the association of  the 
I148M polymorphism with fibrosis appeared larger in 
subjects with at risk alcohol intake (> 30 g/d in males/fe-
males)[76,80], suggesting the existence of  an interaction be-
tween different triggering factors and PNPLA3 genotype 
in fibrogenesis. Furthermore, genetic factors influencing 
immunological response towards HCV, i.e., IL28B region 
polymorphisms, may influence the association between 
PNPLA3 and steatosis[81].
We could speculate that when steatosis inducing 
stressors such as obesity and insulin resistance, excess 
alcohol intake, and HCV infection stress the liver, in the 
presence of  the “normal” 148I PNPLA3 allele the dam-
age will result in simple uncomplicated steatosis, whereas 
the 148M “at risk” allele will favor steatohepatitis and 
fibrogenesis, with progression towards cirrhosis and its 
complication in susceptible individuals[82].
Finally, some studies indicate that during treatment 
with peg-interferon plus ribavirin the I148M polymor-
phism may affect sustained virological response (i.e., cure 
rate)[75] and viral kinetics[83], especially in difficult to cure 
CHC patients with advanced fibrosis[79]. However, the 
clinical impact of  PNPLA3 on the response to therapy 
will likely be modest in the new era of  direct antiviral 
agents[79].
PNPLA3 I148M IN OTHER LIVER 
DISEASES
Having established that the I148M polymorphism is a 
modifier of  the natural history of  liver diseases associ-
ated with steatosis, i.e., NAFLD, ALD and CHC, the pos-
sible role of  I148M in determining the susceptibility to 
steatohepatitis and progressive liver damage in other liver 
diseases is becoming the subject of  investigation.
As it affects more than 350 million people worldwide 
more a epiphenomenon of  insulin resistance and altered 
lipid metabolism than the key driver underpinning liver 
damage progression. Indeed, accumulation of  neutral 
lipids in cytoplasmic droplets is now retained to represent 
a protective response towards the increased burden of  
hepatotoxic free fatty acids and other lipids[14]. Therefore, 
the first question arising after the discovery of  PNPLA3 
genotype as the major determinant of  hepatic fat con-
tent, was whether the I148M polymorphism decreased 
liver damage favoring accumulation of  fatty acids in lipid 
droplets or conversely increased the susceptibility to de-
velop progressive NASH and fibrogenesis.
The answer came soon, as the 148M allele was linked 
with NASH[30], and our group first reported that ho-
mozygosity for the 148M allele was associated with an 
3.3-fold increased risk of  both NASH and liver fibro-
sis in two independent cohorts of  European subjects 
with histological NAFLD[31]. The association between 
PNPLA3 I148M and the severity of  fibrosis in NAFLD 
was almost contemporarily replicated by independent 
groups in adults[34,35] and in the pediatric population[59], 
and confirmed by a recent meta-analysis[36].
ALD shares many pathophysiological features with 
NAFLD[18], most notably steatohepatitis being the key 
driver of  fibrogenesis and liver damage progression. 
Indeed, candidate gene studies demonstrated that the 
I148M polymorphism is also strongly associated with 
the risk of  developing ALD and with the susceptibility 
towards cirrhosis in alcohol abusers of  different ethnic 
groups[60-62]. In one study in German subjects, the I148M 
polymorphism alone explained as much as 26% of  cir-
rhosis variability in alcohol abusers[61]. Furthermore, the 
earlier the age of  the increase at risk alcohol intake the 
stronger the effect of  the PNPLA3 148M mutation has 
on the cirrhosis susceptibility[63].
PNPLA3 I148M AND CHRONIC HCV 
HEPATITIS
The next natural question was clearly whether PNPLA3 
genotype represents a modifier of  progression of  other 
liver diseases in which steatosis plays a key role in the 
pathogenesis. Chronic hepatitis C virus (CHC), a lead-
ing cause of  end stage liver disease and hepatocellular 
carcinoma in many Western countries[64], is frequently 
characterized by steatosis, occurring in more than half  of  
  Study Design Patients Outcome OR 95%CI
  Valenti et al[75] Cross-sectional 819 Cirrhosis 1.5 1.2-1.9
  Müller et al[76] Cross-sectional 605 Cirrhosis 2.8 1.2-6.2
  Trépo et al[77] Cross sectional
prospective
537 Fibrosis stage 3.1 1.5-6.5
Fibrosis progression 2.6 1.2-5.7
Table 1  Studies evaluating the association between the 148 
Isoleucine to Methionine protein variant of patatin-like phos-
pholipase domain-containing 3 polymorphism and liver fibrosis 
in patients affected by chronic hepatitis C virus infection, a 
leading cause of liver related mortality in Western countries
Dongiovanni et al . PNPLA3 and liver disease
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Figure 2  Hypothetical mechanisms linking the 148 Isoleucine to Methionine protein variant of patatin-like phospholipase domain-containing 3 polymor-
phism with hepatic fibrogenesis in the presence of triggering factors for steatosis (Obesity and insulin resistance, excessive alcohol intake and chronic 
hepatitis C virus infection). A: Direct effect of mutant 148 Isoleucine to Methionine protein variant patatin-like phospholipase domain-containing 3 (148M PNPLA3) 
on inflammation, oxidative stress, and cellular damage (ballooning) in hepatocytes with secondary activation of non-parenchymal cells, including Kupffer cells (KC) 
and hepatic stellate cells (HSC). Hepatocytes are shown in brown, KC in light green, neutrophils in dark green, HSC in blue. Nuclei are shown in darker shades of the 
cell color, whereas lipid droplets and steatosis in yellow, and ballooning (endoplasmic reticulum swelling) in white; B: Direct effect of the mutant 148M PNPLA3 on the activation 
of non-parenchymal cells. Mutant PNPLA3 (148Met) is shown as a red box.
and is a leading causes of  liver-related mortality[84], chron-
ic hepatitis B virus (CHB) infection represented the next 
disease in which the role of  PNPLA3 genotype had to be 
understood. Steatosis is indeed commonly observed also 
in CHB, and overall evidence suggests that it contributes 
to fibrosis progression[85-88]. Recent data from our group 
obtained in a relatively large cohort of  European CHB 
patients with histological evaluation of  liver damage indi-
cate that the 148M variant predisposes to steatosis[89]. In 
patients with overweight or a positive history of  alcohol 
intake, the I148M polymorphism predisposes also to 
severe steatosis, which in this population was associated 
with more severe fibrosis[89]. Additional studies will be re-
quired to test the interaction between the I148M genetic 
variant and acquired risk factors in the pathogenesis of  
progressive fibrosis and on related clinical outcomes also 
in CHB infection.
Hereditary hemochromatosis represents another 
interesting disease model. In fact, in a homogeneous ge-
netic background in subjects homozygous for the C282Y 
mutation of  the HFE gene, activation of  fibrogenesis 
is caused by progressive hepatocellular iron overload 
via generation of  oxidative stress[90,91] in the presence of  
precipitating factors, among which steatosis has a major 
role[92]. In a large series of  Italian HFE C282Y homozy-
gous patients with hemochromatosis, we showed that the 
I148M polymorphism is a strong predictor of  the pres-
ence of  steatosis and higher liver enzymes levels, and it is 
also associated with the severity of  fibrosis[93]. A possible 
interaction with other genetic forms of  liver disease (i.e., 
Wilson disease) may also be hypothesized and studies on 
this topic would help understanding the whole picture of 
PNPLA3 gene interaction with liver stressors.
Finally, it has been reported that in primary sclerosing 
cholangitis, an autoimmune cholestatic liver disease char-
acterized by inflammatory changes of  major bile ducts, 
the 148M PNPLA3 variant is associated with increased 
mortality[94]. The effect of  PNPLA3 genotype was evi-
dent in the subgroup of  patients with severe disease, i.e., 
males with stenosis of  the main duct, but unfortunately 
it could not be determined whether the association was 
mediated by steatosis and faster progression of  fibrosis.
Although much work has clearly yet to be done in 
these and many other forms of  liver damage, collectively 
these initial studies suggest that PNPLA3 I148M is a 
promising candidate general modifier of  fibrogenesis in 
liver diseases.
ROLE OF PNPLA3 IN FIBROGENESIS
Intriguingly, the association between the I148M poly-
morphism and NASH appears to be independent of  the 
severity of  steatosis[31], thus suggesting that this genetic 
variant not only influences the overall amount of  hepa-
tocellular fat, but by impacting on the concentration or 
subcellular localization of  specific lipid species directly 
Dongiovanni et al . PNPLA3 and liver disease
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modulates inflammation. It should not be forgotten that 
several lipids behave as inflammatory mediators acting 
through specific receptors[9]. Alternatively, if  the 148M 
mutation slows down triglycerides kinetics between cell 
compartments, it could be speculated that renders them 
more susceptible to lipoperoxidation, leading to oxida-
tive stress, and in turn to hepatocellular damage and 
inflammation[9]. These hypothetical mechanisms linking 
the PNPLA3 148M mutation with hepatic fibrogenesis 
are shown in Figure 2. In the aforementioned scenario, 
shown in panel A, hepatocellular damage and the release 
of  inflammatory mediators would lead to secondary 
activation of  Kupffer cells amplifying the inflammatory 
cascade and cell death, and of  hepatic stellate cells with 
initiation of  fibrogenesis.
Even more striking is though the observation that pa-
tients the I148M polymorphism is associated in NAFLD 
with advanced fibrosis independently of  NASH[31], and 
in CHC with cirrhosis independently of  steatosis, ALT 
levels, and hepatic necroinflammatory activity[75]. It could 
therefore be envisioned that the 148M mutation also 
directly influences the activation of  non-parenchymal he-
patic cells in response to hepatotoxic insults, as shown in 
Figure 2B. This hypothesis needs to be addressed and the 
potential mechanisms investigated by experimental studies.
PNPLA3 I148M AND HEPATOCELLULAR 
CARCINOMA
Last but not least, evidence is also accumulating that the 
I148M polymorphism predisposes to hepatocellular carci-
noma, a common complication of  cirrhosis and the fifth 
cause of  cancer worldwide, with a clinically significant 
increment in risk, thereby representing a potentially use-
ful biomarker[75,95-97]. We have recently reviewed elsewhere 
the clinical studies supporting such an association and 
the potential mechanisms involved[3]. To summarize, data 
indicate that the 148M PNPLA3 mutation favors hepatic 
carcinogenesis in steatohepatitis as well as in other liver 
diseases, and the mechanism is partly independent of  the 
predisposition towards fibrogenesis and cirrhosis.
CONCLUSION
In conclusion, PNPLA3 is a novel key player in liver 
disease progression. Assessment of  the I148M polymor-
phism will possibly inform clinical practice in the future, 
whereas the determination of  the physiological role of  
wild-type PNPLA3 and the 148M variant will reveal 
mechanisms involved in hepatic fibrogenesis and carcino-
genesis and hopefully identify novel therapeutic targets.
REFERENCES
1 Dongiovanni P, Anstee QM, Valenti L. Genetic predispo-
sition in NAFLD and NASH: impact on severity of liver 
disease and response to treatment. Curr Pharm Des 2013; 19: 
5219-5238 [PMID: 23394097]
2 Hirschhorn JN, Gajdos ZK. Genome-wide association stud-
ies: results from the first few years and potential implications 
for clinical medicine. Annu Rev Med 2011; 62: 11-24 [PMID: 
21226609 DOI: 10.1146/annurev.med.091708.162036]
3 Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, 
Romeo S. PNPLA3 I148M variant and hepatocellular car-
cinoma: a common genetic variant for a rare disease. Dig 
Liver Dis 2013; 45: 619-624 [PMID: 23333103 DOI: 10.1016/
j.dld.2012.12.006]
4 Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pen-
nacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic 
variation in PNPLA3 confers susceptibility to nonalcoholic 
fatty liver disease. Nat Genet 2008; 40: 1461-1465 [PMID: 
18820647 DOI: 10.1038/ng.257]
5 Yuan X, Waterworth D, Perry JR, Lim N, Song K, Cham-
bers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson 
T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, 
Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Car-
don L, Frayling TM, Kooner JS, Mooser V. Population-based 
genome-wide association studies reveal six loci influencing 
plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 
520-528 [PMID: 18940312 DOI: 10.1016/j.ajhg.2008.09.012]
6 Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi 
E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda 
N. Nonalcoholic fatty liver disease: a feature of the metabolic 
syndrome. Diabetes 2001; 50: 1844-1850 [PMID: 11473047]
7 Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, 
Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of 
hepatic steatosis in an urban population in the United States: 
impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 
15565570]
8 Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, 
Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk fac-
tors for hepatic steatosis in Northern Italy. Ann Intern Med 
2000; 132: 112-117 [PMID: 10644271]
9 Day CP. From fat to inflammation. Gastroenterology 2006; 
130: 207-210 [PMID: 16401483]
10 Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, 
Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-
Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and 
validation of a histological scoring system for nonalcoholic 
fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 
15915461]
11 Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, 
Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, 
Rizzetto M. Expanding the natural history of nonalcoholic 
steatohepatitis: from cryptogenic cirrhosis to hepatocel-
lular carcinoma. Gastroenterology 2002; 123: 134-140 [PMID: 
12105842]
12 Musso G, Gambino R, Cassader M, Pagano G. Meta-
analysis: natural history of non-alcoholic fatty liver disease 
(NAFLD) and diagnostic accuracy of non-invasive tests for 
liver disease severity. Ann Med 2011; 43: 617-649 [PMID: 
21039302 DOI: 10.3109/07853890.2010.518623]
13 Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, 
Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin 
resistance in non-diabetic patients with non-alcoholic fatty 
liver disease: sites and mechanisms. Diabetologia 2005; 48: 
634-642 [PMID: 15747110]
14 Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey 
SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyc-
eride synthesis improves hepatic steatosis but exacerbates 
liver damage and fibrosis in obese mice with nonalcoholic 
steatohepatitis. Hepatology 2007; 45: 1366-1374 [PMID: 
17476695 DOI: 10.1002/hep.21655]
15 Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, 
muscle, and adipose tissue insulin action is directly related 
to intrahepatic triglyceride content in obese subjects. Gastro-
enterology 2008; 134: 1369-1375 [PMID: 18355813]
16 Targher G, Day CP, Bonora E. Risk of cardiovascular disease 
Dongiovanni et al . PNPLA3 and liver disease
6975 November 7, 2013|Volume 19|Issue 41|WJG|www.wjgnet.com
in patients with nonalcoholic fatty liver disease. N Engl J Med 
2010; 363: 1341-1350 [PMID: 20879883]
17 Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, 
Mozzi E, Leathart JB, Pietrobattista A, Burt AD, Maggioni 
M, Fracanzani AL, Lattuada E, Zappa MA, Roviaro G, Mar-
chesini G, Day CP, Fargion S. Genetic variants regulating 
insulin receptor signalling are associated with the severity 
of liver damage in patients with non-alcoholic fatty liver dis-
ease. Gut 2010; 59: 267-273 [PMID: 20176643 DOI: 10.1136/
gut.2009.190801]
18 Valenti L, Fracanzani AL, Fargion S. The immunopathogen-
esis of alcoholic and nonalcoholic steatohepatitis: two trig-
gers for one disease? Semin Immunopathol 2009; 31: 359-369 
[PMID: 19440711 DOI: 10.1007/s00281-009-0152-9]
19 Lee YS, Jeong WI. Retinoic acids and hepatic stellate cells in 
liver disease. J Gastroenterol Hepatol 2012; 27 Suppl 2: 75-79 
[PMID: 22320921]
20 Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. 
Best Pract Res Clin Gastroenterol 2011; 25: 195-206 [PMID: 
21497738]
21 Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell 
N, Schork NJ, Shiehmorteza M, Yokoo T, Chavez A, Middle-
ton MS, Sirlin CB. Heritability of nonalcoholic fatty liver dis-
ease. Gastroenterology 2009; 136: 1585-1592 [PMID: 19208353 
DOI: 10.1053/j.gastro.2009.01.050]
22 Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic dif-
ferences in hepatic steatosis: an insulin resistance paradox? 
Hepatology 2009; 49: 791-801 [PMID: 19105205 DOI: 10.1002/
hep.22726]
23 Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Con-
treras M, Landt CL, Harrison SA. Prevalence of nonalcoholic 
fatty liver disease and nonalcoholic steatohepatitis among 
a largely middle-aged population utilizing ultrasound and 
liver biopsy: a prospective study. Gastroenterology 2011; 140: 
124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]
24 Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic 
steatohepatitis and cryptogenic cirrhosis within kindreds. 
Am J Med 2000; 108: 9-13 [PMID: 11059435]
25 Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely 
CA. Ninety patients with nonalcoholic steatohepatitis: insu-
lin resistance, familial tendency, and severity of disease. Am 
J Gastroenterol 2001; 96: 2957-2961 [PMID: 11693332]
26 Makkonen J, Pietiläinen KH, Rissanen A, Kaprio J, Yki-
Järvinen H. Genetic factors contribute to variation in serum 
alanine aminotransferase activity independent of obesity 
and alcohol: a study in monozygotic and dizygotic twins. J 
Hepatol 2009; 50: 1035-1042 [PMID: 19303161 DOI: 10.1016/
j.jhep.2008.12]
27 Bathum L, Petersen HC, Rosholm JU, Hyltoft Petersen P, 
Vaupel J, Christensen K. Evidence for a substantial genetic 
influence on biochemical liver function tests: results from 
a population-based Danish twin study. Clin Chem 2001; 47: 
81-87 [PMID: 11148181]
28 Hernaez R, McLean J, Lazo M, Brancati FL, Hirschhorn JN, 
Borecki IB, Harris TB, Nguyen T, Kamel IR, Bonekamp S, 
Eberhardt MS, Clark JM, Kao WH, Speliotes EK. Association 
between variants in or near PNPLA3, GCKR, and PPP1R3B 
with ultrasound-defined steatosis based on data from the 
third national health and nutrition examination survey. Clin 
Gastroenterol Hepatol 2013; 11: 1183-1190.e2 [PMID: 23416328 
DOI: 10.1016/j.cgh.2013.02.011]
29 Kotronen A, Johansson LE, Johansson LM, Roos C, West-
erbacka J, Hamsten A, Bergholm R, Arkkila P, Arola J, 
Kiviluoto T, Fisher RM, Ehrenborg E, Orho-Melander M, 
Ridderstråle M, Groop L, Yki-Järvinen H. A common variant 
in PNPLA3, which encodes adiponutrin, is associated with 
liver fat content in humans. Diabetologia 2009; 52: 1056-1060 
[PMID: 19224197 DOI: 10.1007/s00125-009-1285-z]
30 Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Ros-
selli MS, Pirola CJ. A nonsynonymous gene variant in the 
adiponutrin gene is associated with nonalcoholic fatty liver 
disease severity. J Lipid Res 2009; 50: 2111-2116 [PMID: 
19738004 DOI: 10.1194/jlr.P900013-JLR200]
31 Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, 
Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bu-
gianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. 
Homozygosity for the patatin-like phospholipase-3/adipo-
nutrin I148M polymorphism influences liver fibrosis in pa-
tients with nonalcoholic fatty liver disease. Hepatology 2010; 
51: 1209-1217 [PMID: 20373368]
32 Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, Leonetti 
F, Capoccia D, Incani M, Maglio C, Iacovino M, O’Rahilly S, 
Baroni MG. Morbid obesity exposes the association between 
PNPLA3 I148M (rs738409) and indices of hepatic injury in 
individuals of European descent. Int J Obes (Lond) 2010; 34: 
190-194 [PMID: 19844213]
33 Romeo S, Sentinelli F, Cambuli VM, Incani M, Congiu T, 
Matta V, Pilia S, Huang-Doran I, Cossu E, Loche S, Baroni 
MG. The 148M allele of the PNPLA3 gene is associated 
with indices of liver damage early in life. J Hepatol 2010; 53: 
335-338 [PMID: 20546964 DOI: 10.1016/j.jhep.2010.02.034]
34 Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The as-
sociation of genetic variability in patatin-like phospholipase 
domain-containing protein 3 (PNPLA3) with histological 
severity of nonalcoholic fatty liver disease. Hepatology 2010; 
52: 894-903 [PMID: 20684021 DOI: 10.1002/hep.23759]
35 Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn 
JN. PNPLA3 variants specifically confer increased risk for 
histologic nonalcoholic fatty liver disease but not metabolic 
disease. Hepatology 2010; 52: 904-912 [PMID: 20648472]
36 Sookoian S, Pirola CJ. Meta-analysis of the influence of 
I148M variant of patatin-like phospholipase domain contain-
ing 3 gene (PNPLA3) on the susceptibility and histological 
severity of nonalcoholic fatty liver disease. Hepatology 2011; 
53: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]
37 Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, 
Vajro P. A 360-degree overview of paediatric NAFLD: recent 
insights. J Hepatol 2013; 58: 1218-1229 [PMID: 23238106 DOI: 
10.1016/j.jhep.2012.12.003]
38 Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, 
Nakamura T, Teranishi H, Mizusawa S, Ueno T, Chayama 
K, Nakajima A, Nakao K, Sekine A, Hotta K. Genome-
wide scan revealed that polymorphisms in the PNPLA3, 
SAMM50, and PARVB genes are associated with develop-
ment and progression of nonalcoholic fatty liver disease in 
Japan. Hum Genet 2013; 132: 783-792 [PMID: 23535911 DOI: 
10.1007/s00439-013-1294-3]
39 Peng XE, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X. Genetic 
variants in PNPLA3 and risk of non-alcoholic fatty liver dis-
ease in a Han Chinese population. PLoS One 2012; 7: e50256 
[PMID: 23226254]
40 Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno 
T, Chayama K, Nakajima A, Nakao K, Sekine A. Association 
of the rs738409 polymorphism in PNPLA3 with liver dam-
age and the development of nonalcoholic fatty liver disease. 
BMC Med Genet 2010; 11: 172 [PMID: 21176169 DOI: 10.1186
/1471-2350-11-172]
41 Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A 
common variant in the PNPLA3 gene is a risk factor for non-
alcoholic fatty liver disease in obese Taiwanese children. J 
Pediatr 2011; 158: 740-744 [PMID: 21168155 DOI: 10.1016/
j.jpeds.2010.11.016]
42 Giudice EM, Grandone A, Cirillo G, Santoro N, Amato A, 
Brienza C, Savarese P, Marzuillo P, Perrone L. The associa-
tion of PNPLA3 variants with liver enzymes in childhood 
obesity is driven by the interaction with abdominal fat. PLoS 
One 2011; 6: e27933 [PMID: 22140488]
43 Davis JN, Lê KA, Walker RW, Vikman S, Spruijt-Metz D, 
Dongiovanni et al . PNPLA3 and liver disease
6976 November 7, 2013|Volume 19|Issue 41|WJG|www.wjgnet.com
Weigensberg MJ, Allayee H, Goran MI. Increased hepatic 
fat in overweight Hispanic youth influenced by interaction 
between genetic variation in PNPLA3 and high dietary car-
bohydrate and sugar consumption. Am J Clin Nutr 2010; 92: 
1522-1527 [PMID: 20962157 DOI: 10.3945/ajcn.2010.30185]
44 Santoro N, Savoye M, Kim G, Marotto K, Shaw MM, Pier-
pont B, Caprio S. Hepatic fat accumulation is modulated by 
the interaction between the rs738409 variant in the PNPLA3 
gene and the dietary omega6/omega3 PUFA intake. PLoS 
One 2012; 7: e37827 [PMID: 22629460]
45 Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe 
R, Dykas DJ, Bale AE, Giannini C, Pierpont B, Shaw MM, 
Groop L, Caprio S. Variant in the glucokinase regulatory 
protein (GCKR) gene is associated with fatty liver in obese 
children and adolescents. Hepatology 2012; 55: 781-789 [PMID: 
22105854 DOI: 10.1002/hep.24806]
46 Valenti L, Alisi A, Nobili V. Unraveling the genetics of fatty 
liver in obese children: additive effect of P446L GCKR and 
I148M PNPLA3 polymorphisms. Hepatology 2012; 55: 661-663 
[PMID: 22281838 DOI: 10.1002/hep.25617]
47 Sevastianova K, Santos A, Kotronen A, Hakkarainen A, 
Makkonen J, Silander K, Peltonen M, Romeo S, Lundbom 
J, Lundbom N, Olkkonen VM, Gylling H, Fielding BA, Ris-
sanen A, Yki-Järvinen H. Effect of short-term carbohydrate 
overfeeding and long-term weight loss on liver fat in over-
weight humans. Am J Clin Nutr 2012; 96: 727-734 [PMID: 
22952180 DOI: 10.3945/ajcn.112.038695]
48 He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, 
Cohen JC, Hobbs HH. A sequence variation (I148M) in 
PNPLA3 associated with nonalcoholic fatty liver disease dis-
rupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-6715 
[PMID: 20034933 DOI: 10.1074/jbc.M109.064501]
49 Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs 
HH. A feed-forward loop amplifies nutritional regulation of 
PNPLA3. Proc Natl Acad Sci USA 2010; 107: 7892-7897 [PMID: 
20385813 DOI: 10.1073/pnas.1003585107]
50 Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin 
M, Ståhlman M, Taskinen MR, Orho-Melander M, Per-
man J, Pujia A, Andersson L, Maglio C, Montalcini T, 
Wiklund O, Borén J, Romeo S. Patatin-like phospholipase 
domain-containing 3 (PNPLA3) I148M (rs738409) affects 
hepatic VLDL secretion in humans and in vitro. J Hepa-
tol 2012; 57: 1276-1282 [PMID: 22878467 DOI: 10.1016/
j.jhep.2012.07.030]
51 Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, 
Rangrez AY, Wongsiriroj N, Nagy HM, Ivanova PT, Scott 
SA, Knittelfelder O, Rechberger GN, Birner-Gruenberger R, 
Eder S, Brown HA, Haemmerle G, Oberer M, Lass A, Ker-
shaw EE, Zimmermann R, Zechner R. Adiponutrin functions 
as a nutritionally regulated lysophosphatidic acid acyltrans-
ferase. Cell Metab 2012; 15: 691-702 [PMID: 22560221 DOI: 
10.1016/j.cmet.2012.04.008]
52 Basantani MK, Sitnick MT, Cai L, Brenner DS, Gardner NP, 
Li JZ, Schoiswohl G, Yang K, Kumari M, Gross RW, Zechner 
R, Kershaw EE. Pnpla3/Adiponutrin deficiency in mice does 
not contribute to fatty liver disease or metabolic syndrome. J 
Lipid Res 2011; 52: 318-329 [PMID: 21068004 DOI: 10.1194/jlr.
M011205]
53 Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy 
T, Castro-Perez J, Cohen JC, Hobbs HH. Chronic overexpres-
sion of PNPLA3I148M in mouse liver causes hepatic steato-
sis. J Clin Invest 2012; 122: 4130-4144 [PMID: 23023705 DOI: 
10.1172/JCI65179]
54 Kumashiro N, Yoshimura T, Cantley JL, Majumdar SK, 
Guebre-Egziabher F, Kursawe R, Vatner DF, Fat I, Kahn M, 
Erion DM, Zhang XM, Zhang D, Manchem VP, Bhanot S, 
Gerhard GS, Petersen KF, Cline GW, Samuel VT, Shulman 
GI. Role of patatin-like phospholipase domain-containing 3 
on lipid-induced hepatic steatosis and insulin resistance in 
rats. Hepatology 2013; 57: 1763-1772 [PMID: 23175050 DOI: 
10.1002/hep.26170]
55 Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase 
domain-containing 3/adiponutrin deficiency in mice is 
not associated with fatty liver disease. Hepatology 2010; 52: 
1134-1142 [PMID: 20648554 DOI: 10.1002/hep.23812]
56 Santoro N, Kursawe R, D’Adamo E, Dykas DJ, Zhang CK, 
Bale AE, Calí AM, Narayan D, Shaw MM, Pierpont B, Sa-
voye M, Lartaud D, Eldrich S, Cushman SW, Zhao H, Shul-
man GI, Caprio S. A common variant in the patatin-like 
phospholipase 3 gene (PNPLA3) is associated with fatty liver 
disease in obese children and adolescents. Hepatology 2010; 
52: 1281-1290 [PMID: 20803499]
57 Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani 
L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro 
G, Magni P, Fargion S. The I148M PNPLA3 polymorphism 
influences serum adiponectin in patients with fatty liver and 
healthy controls. BMC Gastroenterol 2012; 12: 111 [PMID: 
22898488 DOI: 10.1186/1471-230X-12-111]
58 Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt 
EM, Unalp A. Relationship of steatosis grade and zonal 
location to histological features of steatohepatitis in adult 
patients with non-alcoholic fatty liver disease. J Hepatol 2008; 
48: 829-834 [PMID: 18321606 DOI: 10.1016/j.jhep.2008.01.016]
59 Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Al-
terio A, Dongiovanni P, Fargion S, Nobili V. I148M patatin-
like phospholipase domain-containing 3 gene variant and 
severity of pediatric nonalcoholic fatty liver disease. Hepatol-
ogy 2010; 52: 1274-1280 [PMID: 20648474]
60 Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds 
DA. Variant in PNPLA3 is associated with alcoholic liver 
disease. Nat Genet 2010; 42: 21-23 [PMID: 19946271 DOI: 
10.1038/ng.488]
61 Stickel F, Buch S, Lau K, Meyer zu Schwabedissen H, Berg T, 
Ridinger M, Rietschel M, Schafmayer C, Braun F, Hinrichsen 
H, Günther R, Arlt A, Seeger M, Müller S, Seitz HK, Soyka 
M, Lerch M, Lammert F, Sarrazin C, Kubitz R, Häussinger D, 
Hellerbrand C, Bröring D, Schreiber S, Kiefer F, Spanagel R, 
Mann K, Datz C, Krawczak M, Wodarz N, Völzke H, Hampe 
J. Genetic variation in the PNPLA3 gene is associated with 
alcoholic liver injury in caucasians. Hepatology 2011; 53: 86-95 
[PMID: 21254164]
62 Stickel F, Hampe J. Genetic determinants of alcoholic 
liver disease. Gut 2012; 61: 150-159 [PMID: 22110053 DOI: 
10.1136/gutjnl-2011-301239]
63 Burza MA, Molinaro A, Attilia ML, Rotondo C, Attilia F, 
Ceccanti M, Ferri F, Maldarelli F, Maffongelli A, De Santis 
A, Attili AF, Romeo S, Ginanni Corradini S. PNPLA3 I148M 
(rs738409) genetic variant and age at onset of at-risk alcohol 
consumption are independent risk factors for alcoholic cir-
rhosis. Liv Int 2013; in press.
64 Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, 
Roudot-Thoraval F. The burden of liver disease in Europe: a 
review of available epidemiological data. J Hepatol 2013; 58: 
593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]
65 Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili 
R, Ruggiero G. Steatosis accelerates the progression of liver 
damage of chronic hepatitis C patients and correlates with 
specific HCV genotype and visceral obesity. Hepatology 2001; 
33: 1358-1364 [PMID: 11391523]
66 Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Ko-
bayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Efficacy 
of interferon monotherapy to 394 consecutive naive cases 
infected with hepatitis C virus genotype 2a in Japan: therapy 
efficacy as consequence of tripartite interaction of viral, host 
and interferon treatment-related factors. J Hepatol 2002; 37: 
831-836 [PMID: 12445425]
67 Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, 
Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro 
P- Reviewers  Bener A    S- Editor  Wen LL    L- Editor  Cant MR    E- Editor  Li JY 
P- Reviewers  Bener A    S- Editor  Song XX    L- Editor  Stewart GJ    E- Editor  Li JY
Dongiovanni et al . PNPLA3 and liver disease
6977 November 7, 2013|Volume 19|Issue 41|WJG|www.wjgnet.com
F. Hepatocyte steatosis is a cytopathic effect of hepatitis C vi-
rus genotype 3. J Hepatol 2000; 33: 106-115 [PMID: 10905593]
68 Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstål R. 
Steatosis accelerates fibrosis development over time in hepa-
titis C virus genotype 3 infected patients. J Hepatol 2002; 37: 
837-842 [PMID: 12445426]
69 Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms 
GL, Neely RD. HCV and the hepatic lipid pathway as a po-
tential treatment target. J Hepatol 2011; 55: 1428-1440 [PMID: 
21718665 DOI: 10.1016/j.jhep.2011.06.004]
70 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and 
disease-specific factors affecting steatosis in chronic hepatitis 
C. J Hepatol 1998; 29: 198-206 [PMID: 9722200]
71 Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Ste-
atosis in chronic hepatitis C: relative contributions of obesity, 
diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-736 
[PMID: 12198667]
72 Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus 
genotype 3 is cytopathic to hepatocytes: Reversal of hepatic 
steatosis after sustained therapeutic response. Hepatology 
2002; 36: 1266-1272 [PMID: 12395339]
73 Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Oku-
da M, Gosert R, Xiao SY, Weinman SA, Lemon SM. Steatosis 
and liver cancer in transgenic mice expressing the structural 
and nonstructural proteins of hepatitis C virus. Gastroenterol-
ogy 2002; 122: 352-365 [PMID: 11832450]
74 Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Morad-
pour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Ne-
gro F, Bochud PY. Viral genotype-specific role of PNPLA3, 
PPARG, MTTP, and IL28B in hepatitis C virus-associated 
steatosis. J Hepatol 2011; 55: 529-535 [PMID: 21236304 DOI: 
10.1016/j.jhep.2010.12.020]
75 Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, 
De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, 
Rametta R, Colombo M, Fargion S. Patatin-like phospholi-
pase domain-containing 3 I148M polymorphism, steatosis, 
and liver damage in chronic hepatitis C. Hepatology 2011; 53: 
791-799 [PMID: 21319195]
76 Müller T, Buch S, Berg T, Hampe J, Stickel F. Distinct, 
alcohol-modulated effects of PNPLA3 genotype on progres-
sion of chronic hepatitis C. J Hepatol 2011; 55: 732-733 [PMID: 
21316406 DOI: 10.1016/j.jhep.2011.01.025]
77 Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, 
Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier 
M, Schlué J, Kreipe H, Devière J, Manns M, Trépo C, Sninsky 
J, Wedemeyer H, Franchimont D, Moreno C. Impact of pa-
tatin-like phospholipase-3 (rs738409 C > G) polymorphism 
on fibrosis progression and steatosis in chronic hepatitis C. 
Hepatology 2011; 54: 60-69 [PMID: 21488075]
78 Cefalù AB, Pirruccello JP, Noto D, Gabriel S, Valenti V, Gup-
ta N, Spina R, Tarugi P, Kathiresan S, Averna MR. A novel 
APOB mutation identified by exome sequencing cosegre-
gates with steatosis, liver cancer, and hypocholesterolemia. 
Arterioscler Thromb Vasc Biol 2013; 33: 2021-2025 [PMID: 
23723369 DOI: 10.1161/ATVBAHA.112.301101]
79 Valenti L, Aghemo A, Stättermayer AF, Maggioni P, De Nic-
ola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Co-
lombo M, Fargion S. Implications of PNPLA3 polymorphism 
in chronic hepatitis C patients receiving peginterferon plus 
ribavirin. Aliment Pharmacol Ther 2012; 35: 1434-1442 [PMID: 
22530607 DOI: 10.1111/j.1365-2036.2012.05109.x]
80 Valenti L, Colombo M, Fargion S. Modulation of the effect of 
PNPLA3 I148M mutation on steatosis and liver damage by 
alcohol intake in patients with chronic hepatitis C. J Hepatol 
2011; 55: 1470-1471; author reply 1471-1472 [PMID: 22100032 
DOI: 10.1016/j.jhep.2011.04.032]
81 Valenti L, Aghemo A, Stättermayer AF. Interaction between 
IL28B and PNPLA3 genotypes in the pathogenesis of steato-
sis in chronic hepatitis C non genotype-3 patients. J Hepatol 
2012; 56: 1209-110; author reply 1209-1210 [PMID: 22230871]
82 Valenti L, Alisi A, Nobili V. 148M PNPLA3 variant and 
progressive liver disease: a new paradigm in hepatology. 
Hepatology 2012; 56: 1883 -1889 [PMID: 23012712]
83 Rembeck K, Maglio C, Lagging M, Christensen PB, Färkkilä 
M, Langeland N, Buhl MR, Pedersen C, Mørch K, Norkrans 
G, Hellstrand K, Lindh M, Pirazzi C, Burza MA, Romeo S, 
Westin J. PNPLA 3 I148M genetic variant associates with 
insulin resistance and baseline viral load in HCV genotype 2 
but not in genotype 3 infection. BMC Med Genet 2012; 13: 82 
[PMID: 22978414 DOI: 10.1186/1471-2350-13-82]
84 European Association For The Study Of The Liver. EASL 
clinical practice guidelines: Management of chronic hepatitis 
B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 
DOI: 10.1016/j.jhep.2012.02.010]
85 Park SH, Kim DJ, Lee HY. Insulin resistance is not associated 
with histologic severity in nondiabetic, noncirrhotic patients 
with chronic hepatitis B virus infection. Am J Gastroenterol 
2009; 104: 1135-1139 [PMID: 19319126]
86 Petta S, Cammà C, Di Marco V, Macaluso FS, Maida M, Piz-
zolanti G, Belmonte B, Cabibi D, Di Stefano R, Ferraro D, 
Guarnotta C, Venezia G, Craxì A. Hepatic steatosis and insu-
lin resistance are associated with severe fibrosis in patients 
with chronic hepatitis caused by HBV or HCV infection. 
Liver Int 2011; 31: 507-515 [PMID: 21382161 DOI: 10.1111/
j.1478-3231.2011.02453.x]
87 Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, 
Chu ES, Cheng AS, Chim AM, Chan FK, Sung JJ, Chan HL. 
Interaction of adipokines and hepatitis B virus on histologi-
cal liver injury in the Chinese. Am J Gastroenterol 2010; 105: 
132-138 [PMID: 19809411 DOI: 10.1038/ajg.2009.560]
88 Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu 
KK, Chan HY, Chan FK, Sung JJ, Chan HL. Metabolic syn-
drome increases the risk of liver cirrhosis in chronic hepatitis 
B. Gut 2009; 58: 111-117 [PMID: 18832522 DOI: 10.1136/
gut.2008.157735]
89 Viganò M, Valenti L, Lampertico P, Facchetti F, Motta BM, D’
Ambrosio R, Romagnoli S, Dongiovanni P, Donati B, Fargion 
S, Colombo M. Patatin-like phospholipase domain-contain-
ing 3 I148M affects liver steatosis in patients with chronic 
hepatitis B. Hepatology 2013; 58: 1245-1252 [PMID: 23564580]
90 Gualdi R, Casalgrandi G, Montosi G, Ventura E, Pietrangelo 
A. Excess iron into hepatocytes is required for activation of 
collagen type I gene during experimental siderosis. Gastroen-
terology 1994; 107: 1118-1124 [PMID: 7926461]
91 Pietrangelo A. Hereditary hemochromatosis--a new look 
at an old disease. N Engl J Med 2004; 350: 2383-2397 [PMID: 
15175440]
92 Wood MJ, Powell LW, Ramm GA. Environmental and ge-
netic modifiers of the progression to fibrosis and cirrhosis 
in hemochromatosis. Blood 2008; 111: 4456-4462 [PMID: 
18316631 DOI: 10.1182/blood-2007-11-122374]
93 Valenti L, Maggioni P, Piperno A, Rametta R, Pelucchi 
S, Mariani R, Dongiovanni P, Fracanzani AL, Fargion S. 
Patatin-like phospholipase domain containing-3 gene I148M 
polymorphism, steatosis, and liver damage in hereditary 
hemochromatosis. World J Gastroenterol 2012; 18: 2813-2820 
[PMID: 22719190 DOI: 10.3748/wjg.v18.i22.2813]
94 Friedrich K, Rupp C, Hov JR, Steinebrunner N, Weiss KH, 
Stiehl A, Brune M, Schaefer PK, Schemmer P, Sauer P, 
Schirmacher P, Runz H, Karlsen TH, Stremmel W, Gotthardt 
DN. A frequent PNPLA3 variant is a sex specific disease 
modifier in PSC patients with bile duct stenosis. PLoS One 
2013; 8: e58734 [PMID: 23505555 DOI: 10.1371/journal.
pone.0058734]
95 Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, 
Franchimont D, Sutton A, Nahon P, Moreno C. PNPLA3 
(rs738409 C > G) is a common risk variant associated with 
hepatocellular carcinoma in alcoholic cirrhosis. Hepatol-
Dongiovanni et al . PNPLA3 and liver disease
6978 November 7, 2013|Volume 19|Issue 41|WJG|www.wjgnet.com
ogy 2012; 55: 1307-1308 [PMID: 22162034 DOI: 10.1002/
hep.25518]
96 Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, Fontanini 
E, Fornasiere E, Bignulin S, Fumolo E, Bignulin E, Pirisi M, 
Toniutto P. PNPLA3 rs738409C/G polymorphism in cirrho-
sis: relationship with the aetiology of liver disease and hepa-
tocellular carcinoma occurrence. Liver Int 2011; 31: 1137-1143 
[PMID: 21745286]
97 Burza MA, Pirazzi C, Maglio C, Sjöholm K, Mancina RM, 
Svensson PA, Jacobson P, Adiels M, Baroni MG, Borén J, 
Ginanni Corradini S, Montalcini T, Sjöström L, Carlsson LM, 
Romeo S. PNPLA3 I148M (rs738409) genetic variant is as-
sociated with hepatocellular carcinoma in obese individuals. 
Dig Liver Dis 2012; 44: 1037-1041 [PMID: 22704398]
P- Reviewers: Loguercio C, Rosenthal P    S- Editor: Zhai HH 
L- Editor: A    E- Editor: Wu HL
Dongiovanni et al . PNPLA3 and liver disease
© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
Published by Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza, 
315-321 Lockhart Road, Wan Chai, Hong Kong, China
Fax: +852-65557188
Telephone: +852-31779906
E-mail: bpgoffice@wjgnet.com
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
4  1
